Antidiabetic pharmaceutical compositions

An oral dosage form of a pharmaceutical composition for managing diabetes or prediabetes in a subject, comprising:

• a core portion comprising a therapeutically effective amount of metformin hydrochloride (metformin HCl);
• an outer portion comprising at least one non-biguanide antidiabetic agent, each at a therapeutically effective amount;
• and
• a controlled membrane film encapsulating the core portion and sandwiched between the core portion and the outer portion, wherein the controlled membrane film is provided with at least one passageway configured to allow the metformin hydrochloride to release out of the core portion therethrough when the oral dosage form is in an aqueous environment;
• wherein:
• the oral dosage form has a dissolution profile such that upon dissolving in a medium with a pH of approximately 6.8 at approximately 37° C.:
• less than 50% of the metformin hydrochloride is released from the oral dosage form at approximately 8 hours;
• and
• no less than 80% of the metformin hydrochloride is released from the oral dosage form at approximately 24 hours.